Rheumatoid Arthritis - Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014

New Delhi, India, August 20, 2014 --(PR.com)-- DelveInsight’s, “Rheumatoid Arthritis-Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014”, report provides comprehensive insights about phase III pipeline drugs and marketed drugs across the indication. A key objective of the report is to establish the understanding for API Manufacturers for marketed and Phase III pipeline drugs across the different countries and regions. While the leading brands, companies and chemicals are considered thoroughly, the report also provides details on the drug master filings across the US, Europe and Asia specifically China and India. The research, analysis also presents the global sales forecasts data till 2015. The report is also giving insight about the patent and exclusivity details of all the drugs across the indication.

Scope
- A snapshot of the global Market therapeutics scenario for Rheumatoid Arthritis.
- A review of the marketed products under prescription for Rheumatoid Arthritis, regulatory information and marketing status.
- Coverage of global patent coverage and detailed commentaries on the US patent challenges.
- Graphical representation of investigational products for patent expiry and market exclusivities across the globe.
- Product profiles for marketed products for Rheumatoid Arthritis with complete description of mechanism of action, therapeutic class, target, route(s) of administration and chemical details.
- Coverage of API Manufacturers for Rheumatoid Arthritis drugs in the United States, Europe and Asian Regions with location details.
- Coverage of Regulatory filings in the US, Europe, and Asia specifically India and China for Rheumatoid Arthritis drugs.
- Coverage of Route of Synthesis of Active Pharmaceutical Ingredient associated with Rheumatoid Arthritis drugs.
- Coverage of Rheumatoid Arthritis Phase III pipeline products featuring sections on product description, mechanism of action, Chemical details and research & development progress.
- Coverage of the United States Drug Master File (US DMF) available for Phase III Pipeline Drugs.
- Key discontinued Marketed products.
- Global Sales Figure from 2011-2015.

Reasons to buy
- Evaluate the marketing status and exclusivity details of Rheumatoid Arthritis key products to exploit opportunities for generic drug development opportunities.
- Identify and understand important and diverse types of therapeutics under Phase III development for Rheumatoid Arthritis.
- Design effective counter-strategies to gain competitive advantage by identifying the key patent expiry details and exclusivity with respect to ‘Disease’.
- API intelligence over marketed drugs for Rheumatoid Arthritis and gaining primary intelligence over active ingredients manufacturers across the globe.
- API intelligence over leading Phase III pipeline drugs.
- Develop and design strategies by identifying the API manufacturers for Phase III pipeline products to enhance and expand business potential and scope.
- Understanding the scope of the Phase III Drugs with nil regulatory filings.
- Understanding the chemical route of synthesis of approved drugs for Rheumatoid Arthritis.
- Uncovering opportunities in the rapidly growing the US markets.

Table of Contents
- Indication Overview
- Marketed Drugs Assessment
- Marketed Details of Drugs by Application Type
- Marketed Details of Drugs (NDA) by Marketing Status
- Marketed Details of Drugs by Patent Expiration Timeline
- The Active Pharmaceutical Ingredient (API) Manufacturers Assessment
- The API Manufacturers by the United States Drug Master File (US DMF) Status
- The API Manufacturers by the US DMF Status (Drug Specific)
- The Active Pharmaceutical Ingredient (API) Manufacturers Assessment for Phase III Pipeline Drugs
- The API Manufacturers by the US DMF Status (Drug Specific)
- Drugs Market Data and Forecasted Sales Figures (2011-2015)
- Marketed Drugs Information
- Drugs Description
- Route of Synthesis
- Global Active Pharmaceutical Manufacturers
- Approval Status
- Patent and Exclusivity Details
- Company Overview
- Phase III Drugs Information
- Phase III Drugs Description
- The United States Drug Master Filings (US DMF)
- Discontinued Drugs Information

List of Tables
Rheumatoid Arthritis Therapeutic Market, US, Marketed Drugs by Application Type, 2014
Rheumatoid Arthritis Therapeutic Market, US, Marketed Drugs by Marketing Status, 2014
Rheumatoid Arthritis Therapeutic Market, US, (Year), 2014
Rheumatoid Arthritis Marketed Drugs, API Manufacturers by US DMF Status, 2014
Rheumatoid Arthritis Marketed Drugs, US DMF Status Drug Specific (Number), 2014
Rheumatoid Arthritis Phase III Pipeline Drugs, US DMF Status Drug Specific (Number), 2014
Rheumatoid Arthritis Therapeutic Market, Global Sales (in million USD), 2014
Rheumatoid Arthritis Marketed Drugs, API Manufacturers, Global, 2014
Rheumatoid Arthritis Phase III Pipeline Drugs, United States Drug Master File (DMF), 2014
Discontinued Drugs for Rheumatoid Arthritis, 2014

List of Figures
Rheumatoid Arthritis Therapeutic Market, US, Marketed Drugs by Application Type (%), 2014
Rheumatoid Arthritis Therapeutic Market, US, Marketed Drugs by Marketing Status (%), 2014
Rheumatoid Arthritis Therapeutic Market, US, (Year), 2014
Rheumatoid Arthritis Marketed Drugs, API Manufacturers by US DMF Status (%), 2014
Rheumatoid Arthritis Marketed Drugs, US DMF Status Drug Specific (Number), 2014
Rheumatoid Arthritis Phase III Pipeline Drugs, US DMF Status Drug Specific (Number), 2014
Rheumatoid Arthritis Therapeutic Market, Global Sales (in million USD), 2014
Rheumatoid Arthritis Marketed Drugs, Patent/Exclusivity Expiry (Year), 2014

Report Pricing

Single User: USD 2000
Site License: USD 4000
Global License: USD 6000

To order this report please contact below: